Compass Therapeutics (NASDAQ:CMPX) Trading Down 7.6% - Here's Why

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report)'s share price fell 7.6% during trading on Tuesday . The company traded as low as $3.60 and last traded at $3.61. 1,262,924 shares changed hands during trading, a decline of 47% from the average session volume of 2,397,288 shares. The stock had previously closed at $3.90.

Analyst Ratings Changes

A number of research firms recently commented on CMPX. Leerink Partners cut Compass Therapeutics from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. D. Boral Capital reiterated a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Jefferies Financial Group lifted their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Monday, February 10th. Finally, Leerink Partnrs cut Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $11.17.

Compass Therapeutics Trading Down 2.0 %

The firm has a market capitalization of $465.05 million, a price-to-earnings ratio of -9.13 and a beta of 1.17. The firm has a 50 day moving average price of $2.28 and a two-hundred day moving average price of $1.81.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. As a group, research analysts forecast that Compass Therapeutics, Inc. will post -0.35 earnings per share for the current year.

Hedge Funds Weigh In On Compass Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Rock Springs Capital Management LP lifted its position in Compass Therapeutics by 2.7% during the 4th quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company's stock worth $8,380,000 after acquiring an additional 150,336 shares in the last quarter. Blue Owl Capital Holdings LP lifted its position in Compass Therapeutics by 2.6% during the 4th quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company's stock worth $4,284,000 after acquiring an additional 75,000 shares in the last quarter. Geode Capital Management LLC lifted its position in Compass Therapeutics by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 2,334,171 shares of the company's stock worth $3,386,000 after acquiring an additional 24,393 shares in the last quarter. SG Americas Securities LLC lifted its position in Compass Therapeutics by 921.6% during the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock worth $573,000 after acquiring an additional 356,352 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in Compass Therapeutics by 25.2% during the 4th quarter. Renaissance Technologies LLC now owns 278,600 shares of the company's stock worth $404,000 after acquiring an additional 56,000 shares in the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.